Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Australia Accepts Three Approval Pathways, Defers Registry For High-Risk Devices

Executive Summary

The Australian government plans to introduce a series of regulatory reforms for devices and drugs over a period of three years, including moves to speed up access to innovative devices and to better leverage assessments by overseas regulators. The changes may include some recovery of costs from industry.


Related Content

Australia To Make Access To Unauthorized Products Faster And Less Bothersome
Australia Steps Up Priority Review And Faster Assessment Plans
Australia’s 'Unrealistic' Randomized Controlled Trial Proposal Comes Under Fire
Australia to ease regulatory burden for devices and drugs